OncoCyte has next gen cancer diagnostics coming 1stQ 17, AST spine trial and dancer vaccine also 2017 news.....also of note, Biotime product Renevia also out on market in 2017. For those who don't know, Renevia is a next-gen cosmetic surgery product using a patients own fat cells in combination with BTX's extra-cellular matrix hydrogel.
BTX stock is a BUY, should be closer to $12 early next year as these game changing products start to be released.
My feeling is that OncoCyte's cancer diagnostic products will make some waves. Out by late 2017, perfect timing as cancer diagnostic/treatment will within five years be totally treatable.
Big pharma will snap OncoCyte for no less then 400 MIL. Make no mistake cancer is big business and BTX is ahead of the curve with industry leading ip 5+ years in the making.
After the buyout BTX's huge profits will then move heart regen and cancer therapies into clinical trials and within 5 years become a must have biotech stock.